Alok Khorana, MD
@aakonc
Followers
5K
Following
45K
Media
607
Statuses
10K
Hardis Endowed Chair, FACP, FASCO, Prof Med, Vice Chair Taussig Cancer Ctr, Dir GI Cancers, @ClevelandClinic. Writer. Opinions my own. I have #FCOI.
Cleveland, Ohio
Joined December 2011
My new piece on @DalrympleWill's Golden Road, which releases this week in the US- A Deeply Globalized Ancient World https://t.co/ziaX4Rri27 via @lithub
lithub.com
It was my first visit to Tokyo. Thanks to a lost-in-translation miscommunication with my scientific colleagues, I found myself with an unexpectedly open daytime schedule. This is how I ended up alo…
4
9
35
Cryoablation plus sintilimab & lenvatinib in advanced intrahepatic cholangiocarcinoma: a phase 2 trial @NatureCancer
https://t.co/6YZz7zzibf 👉Interesting approach 👉ORR 75%, mPFS 16.8 mo, mOS 25.4 months 🧐Seems to be very promising @myESMO @EASLedu @ILCAnews @curecca
2
15
38
Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in MSS BRAF V600E mCRC @Cancer_Cell
https://t.co/9lrrhuHjSj 👉ORR 50%, mPFS 7.4 mo 🧐Subgroup of mCRC with baseline MAPK activation & immune activation signatures may benefit from the triplet @myESMO
1
9
32
727MO: OPTIPRIME study, FOLFOX + Pani "stop-and-go" strategy ✅Duration of disease control 24.9 mo ✅1st re-introduction ORR: 45.0% ✅OS 36.1 mo 👉Want to know toxicity profiles including neuropathy with oxaliplatin re-introduction #ESMO25 @myESMO @OncoAlert
2
12
20
Yet another athlete impacted by a #bloodclot Wishing @BuffaloSabres player #JiriKulich a full and speedy recovery Learn more about athletes & #bloodclots @StopTheClot @NHL
sports.yahoo.com
Ruff didn’t provide any further details except to say it’s “pretty serious,” and that the second-year player will miss “significant time.”
1
1
5
It’s incredible to see how my colleague Dr. Ross Camidge has handled his diagnosis with such grace and courage while continuing to serve his patients. His interview on @COPublicRadio is here for those who may not have heard it.
#CUAnschutz oncologist D. Ross Camidge, MD, PhD, has spent his career helping patients face lung cancer. Now, he's facing the disease himself – and sharing his story about his diagnosis in an effort to de-stigmatize terminal illness. | @COPublicRadio
0
2
9
Satellite lesions vs intrahepatic metastasis in multifocal intrahepatic cholangiocarcinoma: Prognostic impact and genomic profiling @HEP_Journal
https://t.co/PLHIy9oUCQ 👉highly concordant mutational landscape of IM & SL 👉 poor long-term survival 🧐both should be categorized
0
14
48
Wishing #FilipHallander a quick recovery from his #bloodclot & thankful that the @penguins medical team identified it quickly. So important people know the signs & symptoms of #bloodclots Learn more @StopTheClot Filip Hallander Out At Least Three Months with Blood Clot
nhl.com
The team announced on Friday that Filip Hallander has been diagnosed with a blood clot in his leg and will miss a minimum of three months. The 24-year-old forward will remain in Pittsburgh and rehab...
1
2
5
Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notable variation by cancer type and absence of cancer-specific guidelines. https://t.co/upXIWf6cg2
0
24
93
Today I learned that if someone has coronary vasospasm on infusional 5-FU, in select patients you can still give them bolus 5-FU if they’re low risk (a regimen called FLOX). Because the half life is so short, with bolus the arteries aren’t exposed to 5-FU long enough to spasm.
2
8
83
We looked at this exact question and found that high TMB after targeted therapy, which is more striking in plasma than in tissue, is not sufficient to engender a response to immunotherapy. Manuscript just out!
aacrjournals.org
Abstract. Purpose: Microsatellite stable (MSS) colorectal cancers (CRCs), in contrast to microsatellite instability-high (MSI-H) CRCs, have few mutations and are insensitive to immune checkpoint...
High-TMB after anti-EGFR therapy in MSS CRC @ESMO_Open ✅TMB ≥10 (after vs before anti-EGFR): 33.8% vs 9.7% ✅Higher alterations of MAPK signaling 👉Could high-TMB accompanied by "subclonal" alterations after anti-EGFR therapy be a target for immunotherapy?
3
15
57
🔥🔥🔥
Fantastic. Will transform women’s cricket in the same way that the Indian men’s triumph in the 2007 World T20 transformed the men’s game. Brave performance by South Africa too. Great advert for women’s cricket. #ICCWomensWorldCup2025
0
0
2
💬 Editorial: Consistent long-term physical activity—about 17 metabolic equivalent task-hours/week over 30 years—was linked to optimally reduced risk of digestive system cancers. https://t.co/YnKRVsskFb
0
3
15
Type IV gastric NET, the one associated with PPIs... More data pointing to a subset of gastric NETs associated with long-term PPI use, often called type IV. Compared to type III, type IV is much more indolent and less likely to metastasize. https://t.co/uy7NrQw49t
1
15
48
Does chemotherapy affect the biology of BRAF V600E mCRC when combined with encorafenib + ceruximab? Answer appears to be YES! Very intriguing translational finding showing that addition of chemo to E+C reduces development of acquired RAS, MAP2K1 , and other mutations that drive
4
37
121
.@NatureGenet paper by @BizarMd @columbiacancer Cellular states associated with metastatic organotropism & survival in patients with #PancreaticCancer “pre-existing cellular states within primary tumors appear to guide organ-specific metastatic relapse” https://t.co/omZzPO6P78
4
41
164
So excited for the @StopTheClot @nycmarathon to take to the streets on November 2nd!!!! Also excited for @StopTheClot Coach @SageCanaday to lead the shakeout run on November 1st! 🏃♀️ 🏃🏾♂️🏃
Congrats to NBCA Coach @SageCanaday! 🎉Sage crushed the @JavelinaJundred & now heads to NY to coach #TeamStopTheClot in the @nycmarathon team on Sunday! 🗽Huge thanks to @hoka, @nyrr & #tcsnycmarathon for helping make this journey possible. Let’s do this, Team Stop the Clot! 🙌
0
2
4
Women derive more benefit from physical activity than men with respect to reduction of cardiovascular risk and related mortality, and can achieve protection at lower levels of engagement. From ~85,000 participants, open-access (blue=men) https://t.co/gfaPgCna4o
8
198
709
Very proud and happy to share that our work on neoadjuvant IO in pMMR colon cancers has been published online in @Nature after presentation @myESMO #ESMO25. Preview: https://t.co/KR6mBytwV3 Read on how genomic instability, P53mt and proliferation may aid in predicting responses.
22
120
502
cT3/T4 per CT identifies patients with dMMR colon cancer with substantial risk of recurrence despite FOLFOX: cT3N0: 84% 3-year DFS cT4N0: 70% 3-year DFS Of course, NICHE2 : 100% 3-year DFS for cT3/4 For patients with dMMR colon cancer cT3/T4 by CT: we should discuss risks and
Proud to present combined NICHE-2 & FOXTROT analysis in dMMR locally advanced CC -Neoadjuvant IO superior to chemo -20% relapses with chemo in "good prognosis" group; 30% if T4 -Minimal path response to chemo - Clinical staging identified high risk group
1
37
82
Chronic atrophic gastritis increases risk of gastric NETs (gNETs) and adenocarcinoma. Among 199 pts at risk for gNETs, the 5- and 10-year cumulative incidence was 6% and 18%. Hypergastrinemia and alcohol use were associated with increased risk of gNETs. https://t.co/fXoBhCKwAi
1
8
18